Phaseline

Targets › KLKB1

KLKB1 (Plasma kallikrein): drug programs, companies and trials

8 programs from 8 companies in 12 trials: 5 Phase 3, 4 Phase 2, 2 Phase 4, 1 Phase 1; Immunology, Neurology, Ophthalmology; next expected readout Nov 2026.

Participates in the surface-dependent activation of blood coagulation. Activates, in a reciprocal reaction, coagulation factor XII/F12 after binding to negatively charged surfaces. (UniProt, P03952)

Open in Phaseline: the race on KLKB1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bernstein Clinical Research CenterLanadelumab
Plasma kallikrein inhibitor
KLKB1Phase 4AngioedemaSep 2027
KalVista Pharmaceuticalssebetralstat (KVD900)
Plasma kallikrein inhibitor
KLKB1Phase 4Hereditary AngioedemaNov 2027
BioCryst PharmaceuticalsBerotralstat
Plasma kallikrein inhibitor
KLKB1Phase 3Hereditary AngioedemaFeb 2027
Pharvaris NetherlandsDeucrictibant
Plasma kallikrein inhibitor
KLKB1Phase 3Hereditary Angioedema (HAE); Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)Jun 2027
ADARx PharmaceuticalsADX-324
siRNA duplex oligonucleotide targeting KLKB1
KLKB1Phase 3Hereditary Angioedema; Hereditary Angioedema (HAE)Nov 2027
Kyowa KirinKHK4951
Kallikrein-bradykinin pathway inhibitor
KLKB1Phase 2Neovascular Age-Related Macular Degeneration (nAMD); Diabetic Macular Edema (DME)Nov 2026
DiaMedica TherapeuticsDM199
Recombinant human tissue kallikrein (rinvecalinase alfa) - serine protease that activates
KLKB1Phase 2Acute StrokeDec 2026
General Hospital of Shenyang Military RegionHuman Urinary Kallidinogenase
Tissue kallikrein that converts kininogen into kallidin and kinins; promotes vascular endo
KLKB1Phase 2Ischemic StrokeSep 2027

Conditions

Hereditary Angioedema (4) Hereditary Angioedema (HAE) (2) Neovascular Age-Related Macular Degeneration (nAMD) (1) Diabetic Macular Edema (DME) (1) Ischemic Stroke (1) Angioedema (1) Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) (1) Acute Stroke (1)

Modalities

small molecule (4), mixed (1), other (1), protein or peptide (1), antibody (1)

Companies

Kyowa Kirin (1) KalVista Pharmaceuticals (1) BioCryst Pharmaceuticals (1) ADARx Pharmaceuticals (1) General Hospital of Shenyang Military Region (1) Bernstein Clinical Research Center (1) Pharvaris Netherlands (1) DiaMedica Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.